Niihara Yutaka's Form 4 filing
Emmaus Life Sciences, Inc. (EMMA) · filed Oct 12, 2022
- Accession no.
- 0001209191-22-053433
- Filed
- Oct 12, 2022, 1:04 PM ET
- Trade date
- Sep 26-Oct 11, 2022
- Filing delay
- 16 daysLate
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 9 non-derivative transactions and 0 derivative transactions. Open-market purchases total $20.4K. It was filed 16 days after the trade, past the 2-business-day deadline.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Niihara YutakaCIK 0001517691 | Director, Officer (Chairman and CEO), 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 26, 2022 | Common stock, $0.001 par value | PPurchaseAcquired | +6,000 | $0.20 | +$1,200 | 11,339,857 | Direct | |
| Sep 27, 2022 | Common stock, $0.001 par value | PPurchaseAcquired | +5,000 | $0.20 | +$1,000 | 11,344,857 | Direct | |
| Oct 3, 2022 | Common stock, $0.001 par value | PPurchaseAcquired | +10,000 | $0.20 | +$2,000 | 11,354,857 | Direct | |
| Oct 4, 2022 | Common stock, $0.001 par value | PPurchaseAcquired | +5,000 | $0.16 | +$800 | 11,359,857 | Direct | |
| Oct 5, 2022 | Common stock, $0.001 par value | PPurchaseAcquired | +10,000 | $0.15 | +$1,500 | 11,369,857 | Direct | |
| Oct 6, 2022 | Common stock, $0.001 par value | PPurchaseAcquired | +5,000 | $0.15 | +$750 | 11,374,857 | Direct | |
| Oct 7, 2022 | Common stock, $0.001 par value | PPurchaseAcquired | +4,000 | $0.13 | +$520 | 11,378,857 | Direct | |
| Oct 10, 2022 | Common stock, $0.001 par value | PPurchaseAcquired | +10,000 | $0.09 | +$900 | 11,388,857 | Direct | |
| Oct 11, 2022 | Common stock, $0.001 par value | PPurchaseAcquired | +130,000 | $0.09 | +$11,700 | 11,518,857 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.